ConductScience.org, home

Paper41377006

Prediction of EGFR mutation status and mutation sites in lung cancer based on radiomics and deep learning.

Zeng Z and 7 others. J Thorac Dis, 2025. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Prediction of EGFR mutation status and mutation sites in lung cancer based on radiomics and deep learning. Papers, record 41377006. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41377006

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Prediction of EGFR mutation status and mutation sites in lung cancer based on radiomics and deep learning.
PubMed
Journal
J Thorac Dis
PubMed
Year
2025
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2025-12-13
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Zeng ZZheng
2Zhang RRui
3Dong YYucai
4Liu BBaocong
5Ma HHuiyun
6Zheng YYuquan
7Gao XXinhttps://orcid.org/0000-0001-9906-0596
8Li QQionghttps://orcid.org/0000-0001-9044-0074

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References33

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
138880172Prevalence of EGFR Mutations in Patients With Resected Stages I to III NSCLC: Results From the EARLY-EGFR Study.J Thorac Oncol2024https://conductscience.org/library/papers/38880172PubMed
229864379Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.J Clin Oncol2018https://conductscience.org/library/papers/29864379PubMed
328367239Efficacy of Second-line Tyrosine Kinase Inhibitors in the Treatment of Metastatic Advanced Non-small-cell Lung Cancer Harboring Exon 19 and 21 EGFR Mutations.J Cancer2017https://conductscience.org/library/papers/28367239PubMed
414570950Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.JAMA2003https://conductscience.org/library/papers/14570950PubMed
535669165EGFR Mutation Status and Subtypes Predicted by CT-Based 3D Radiomic Features in Lung Adenocarcinoma.Onco Targets Ther2022https://conductscience.org/library/papers/35669165PubMed
632853681Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group.Ann Oncol2020https://conductscience.org/library/papers/32853681PubMed
723780873EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in non-small cell lung carcinoma patients.Cancer Cytopathol2013https://conductscience.org/library/papers/23780873PubMed
831278276Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma.Nat Commun2019https://conductscience.org/library/papers/31278276PubMed
940328536Prediction of EGFR Mutations in Lung Adenocarcinoma via CT Images: A Comparative Study of Intratumoral and Peritumoral Radiomics, Deep Learning, and Fusion Models.Acad Radiol2025https://conductscience.org/library/papers/40328536PubMed
1023749122Routine EGFR molecular analysis in non-small-cell lung cancer patients is feasible: exons 18-21 sequencing results of 753 patients and subsequent clinical outcomes.Lung2013https://conductscience.org/library/papers/23749122PubMed
1133067442Non-invasive decision support for NSCLC treatment using PET/CT radiomics.Nat Commun2020https://conductscience.org/library/papers/33067442PubMed
1226490356
Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine kinase inhibitors treatment: a meta-analysis.
Eur J Clin Pharmacol2016https://conductscience.org/library/papers/26490356PubMed
13329534993D radiomics predicts EGFR mutation, exon-19 deletion and exon-21 L858R mutation in lung adenocarcinoma.Transl Lung Cancer Res2020https://conductscience.org/library/papers/32953499PubMed
1426937803CT Features Associated with Epidermal Growth Factor Receptor Mutation Status in Patients with Lung Adenocarcinoma.Radiology2016https://conductscience.org/library/papers/26937803PubMed
1524419411A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER).J Thorac Oncol2014https://conductscience.org/library/papers/24419411PubMed
1628958502Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.Lancet Oncol2017https://conductscience.org/library/papers/28958502PubMed
1721725039Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations.J Clin Pathol2011https://conductscience.org/library/papers/21725039PubMed
1829151359Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.N Engl J Med2018https://conductscience.org/library/papers/29151359PubMed
1935341713Mining whole-lung information by artificial intelligence for predicting EGFR genotype and targeted therapy response in lung cancer: a multicohort study.Lancet Digit Health2022https://conductscience.org/library/papers/35341713PubMed
2034502160Machine Learning-Based Radiomics Signatures for EGFR and KRAS Mutations Prediction in Non-Small-Cell Lung Cancer.Int J Mol Sci2021https://conductscience.org/library/papers/34502160PubMed

See all 33 referencesDownload CSV of references

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
EGFR1956PubTator's text mininghttps://conductscience.org/library/genes/1956

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41377006

GET https://conductscience.org/api/papers/v1/41377006/references?page=2